基于估计信息时间权重的样本量重新估计方法

熊航乐 ,  巩浩雯 ,  刘玉秀 ,  王静怡 ,  倪咏天 ,  李维勤

中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (7) : 885 -891.

PDF (2733KB)
中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (7) : 885 -891. DOI: 10.12092/j.issn.1009-2501.2026.07.003

基于估计信息时间权重的样本量重新估计方法

作者信息 +

Sample size re-estimation method based on estimated information time weighting

Author information +
文章历史 +
PDF (2798K)

摘要

目的: 提出一种新的条件把握度(conditional power,CP)算法,并用于样本量重新估计(sample size re-estimation,SSR)。方法: 根据期中观察到的结果估计出一个临时样本量,然后以当前样本量占该估计样本量的比例作为权重,即估计信息时间权重(estimated information time weighting,EIW),计算 CP(cpEIW)并进行样本量重新估计。借助 Monte-Carlo 模拟技术对该方法与目前计算 CP 常用的cpI法(初始假定参数法)、cpD法(期中观测结果法)和cpOPW法(最优混合权重法)3 种方法进行准确性比较,并比较基于 4 种 CP 算法进行样本量重新估计的统计性能。结果: 对 CP 准确性的模拟结果显示,cpEIW和cpT的准确性接近,且两者均优于常用的cpI和cpD。对基于不同 CP 算法进行样本量重新估计的模拟结果显示,4 种方法均能够控制一类错误,而cpEIW法具有最高的把握度,同时具有最优的平均性能得分(APS)。结论: 在 4 种 CP 算法中,cpEIW法具有较好的准确性,用其进行样本量重新估计也具有较好的统计性能,可推荐应用。

Abstract

AIM: To propose a new conditional power (CP) algorithm and apply it to sample size re-estimation (SSR). METHODS: A temporary sample size was estimated based on the interim observed results, and the ratio of the current sample size to this estimated sample size was used as the weight, referred to as the estimated information time weighting (EIW). CP (cpEIW) was calculated using this weighting, and sample size re-estimation is performed. Monte Carlo simulation techniques were used to compare the accuracy of this method with three commonly used CP calculation methods: cpI method (initial assumed parameter method), cpD method (interim observation result method), and cpOPW method (optimal hybrid weight method). Additionally, the statistical performance of sample size re-estimation based on four different CP algorithms was compared. RESULTS: Simulation results for CP accuracy showed that the accuracy of cpEIW and cpT were close, and both outperform the commonly used cpI and cpD. For sample size re-estimation based on different CP algorithms, all four methods were able to control type Ⅰ error, with cpEIW showing the highest conditional power and the best average performance score (APS). CONCLUSION: Among the four CP algorithms, cpEIW exhibits good accuracy and provides better statistical performance for sample size re-estimation. It is recommended for application.

关键词

临床试验 / 适应性设计 / 条件把握度 / 样本量重新估计 / 估计信息时间权重

Key words

clinical trials / adaptive design / conditional power / sample size re-estimation / estimated information time weighting

引用本文

引用格式 ▾
熊航乐,巩浩雯,刘玉秀,王静怡,倪咏天,李维勤. 基于估计信息时间权重的样本量重新估计方法[J]. 中国临床药理学与治疗学, 2026, 31(7): 885-891 DOI:10.12092/j.issn.1009-2501.2026.07.003

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

国家药品监督管理局药品评审中心. 药物临床试验适应性设计指导原则 (试行)[EB/OL]. (2021-01-29)[2024-12-10].https://www.cde.org.cn/zdyz/domesticinfopage?zdyzIdCODE=4409e51a403a911757af6caf3ecef129.

[2]

Chen YH, DeMets DL, Lan KKG.Increasing the sample size when the unblinded interim result is promising[J].Stat Med, 2004, 23(7): 1023-1038.

[3]

Denne JS.Sample size recalculation using conditional power[J].Stat Med, 2001, 20(17/18): 2645-2660.

[4]

Gao P, Ware JH, Mehta C.Sample size re-estimation for adaptive sequential design in clinical trials[J].J Biopharmac Stat, 2008, 18(6): 1184-1196.

[5]

Mehta C, Pocock SJ.Adaptive increase in sample size when interim results are promising: a practical guide with examples[J].Stat Med, 2011, 30(28): 3267-3284.

[6]

Lachin JM.A review of methods for futility stopping based on conditional power[J].Stat Med, 2005, 24(18): 2747-2764.

[7]

Pong A, Chow SC. Handbook of adaptive designs in pharmaceutical and clinical development[M]. Boca Raton, Florida: CRC Press,2011: 94-110.

[8]

Glimm E. Comments on ‘Adaptive increase in sample size when interim results are promising: a practical guide with examples’[J].Stat Med, 2012, 31(1): 98-99.

[9]

Zhu J, Li X, Liu Y.An optimal hybrid approach to calculate conditional power[J].Stat Biopharmac Res, 2022, 14(4): 480-492.

[10]

Jennison C, Turnbull BW. Adaptive sample size modification in clinical trials: start small then ask for more ?[J].Stat Med, 2015, 34(29): 3793-3810.

[11]

Proschan MA, Lan G, Wittes JT. Statistical monitoring of clinical trials: a unified approach[M]. New York: Springer Science Business Media,2006: 43-60.

[12]

Lan KK, Wittes J.The B-value: a tool for monitoring data[J].Biometrics, 1988, 44(2): 579-585.

[13]

Cui L, Hung HM, Wang SJ.Modification of sample size in group sequential clinical trials[J].Biometrics, 1999, 55(3): 853-857.

[14]

Wang P, Chow SC.Sample size re-estimation in clinical trials[J].Stat Med, 2021, 40(27): 6133-6149.

[15]

Liu GF, Zhu GR, Cui L.Evaluating the adaptive performance of flexible sample size designs with treatment difference in an interval[J].Stat Med, 2008, 27(4): 584-596.

[16]

Kapadia SR, Makkar R, Leon M, et al. Cerebral embolic protection during transcatheter aortic -valve replacement[J].New Engl J Med, 387(2022): 1253-1263.

[17]

Xiong Y, Campbell BCV, Schwamm LH, et al. Tenecteplase for ischemic stroke at 4.5 to 24 hours without Thrombectomy[J].N Engl J Med, 2024, 391: 203-212.

[18]

Yeh RW, Shlofmitz R, Moses J, et al. Paclitaxel-Coated Balloon vs Uncoated Balloon for Coronary In-Stent Restenosis: The AGENT IDE Randomized Clinical Trial[J].JAMA, 2024, 331(12): 1015-1024.

基金资助

国家自然科学基金面上项目(81473066)

AI Summary AI Mindmap
PDF (2733KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉